American Chemistry Council (ACC) - Comment

Document ID: FDA-2013-N-0222-0006
Document Type: Public Submission
Agency: Food And Drug Administration
Received Date: May 14 2013, at 12:00 AM Eastern Daylight Time
Date Posted: May 21 2013, at 12:00 AM Eastern Standard Time
Comment Start Date: March 18 2013, at 12:00 AM Eastern Standard Time
Comment Due Date: May 17 2013, at 11:59 PM Eastern Standard Time
Tracking Number: 1jx-85bo-9qg3
View Document:  View as format xml

View Comment

See attached file(s) The American Chemistry Council (ACC) appreciates the opportunity to provide written comments on the Food and Drug Administration’s (FDA) consideration of “Proposed change to rodent carcinogenicity testing of pharmaceuticals” - the International Conference on Harmonization (ICH) S1 guidance on rodent carcinogenicity testing. It’s our view that the FDA’s proposal to implement the requirement for submission of carcinogenicity assessment documents, in lieu of performing a two-year rat carcinogenicity study, is a sound approach that should be pursued. Richard A. Becker, Ph.D. DABT

Attachments:

American Chemistry Council ACC Comments FDA Triggered CA Study 14 May 2013

Title:
American Chemistry Council ACC Comments FDA Triggered CA Study 14 May 2013

View Attachment: View as format pdf

Related Comments

    View All
Total: 11
American Chemistry Council (ACC) - Comment
Public Submission    Posted: 05/21/2013     ID: FDA-2013-N-0222-0006

May 17,2013 11:59 PM ET
Bristol-Myers Squibb - Comment
Public Submission    Posted: 05/21/2013     ID: FDA-2013-N-0222-0007

May 17,2013 11:59 PM ET
Society of Toxicologic Pathology - Comment
Public Submission    Posted: 05/21/2013     ID: FDA-2013-N-0222-0002

May 17,2013 11:59 PM ET
Novartis Pharmaceuticals Corp. - Comment
Public Submission    Posted: 05/21/2013     ID: FDA-2013-N-0222-0004

May 17,2013 11:59 PM ET
BioReliance - Comment
Public Submission    Posted: 05/21/2013     ID: FDA-2013-N-0222-0010

May 17,2013 11:59 PM ET